189 related articles for article (PubMed ID: 21883840)
1. Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
Costa R; Wesolowski R; Raghavan D
BJU Int; 2011 Nov; 108(10):1546-54. PubMed ID: 21883840
[TBL] [Abstract][Full Text] [Related]
2. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic chemotherapy for adrenocortical carcinoma.
Dogliotti L; Berruti A; Pia A; Paccotti P; Alì A; Angeli A
Minerva Endocrinol; 1995 Mar; 20(1):105-9. PubMed ID: 7544429
[TBL] [Abstract][Full Text] [Related]
5. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
Demeure MJ; Somberg LB
Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive treatment of adrenocortical carcinoma.
Terzolo M; Berruti A
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
8. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
9. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
10. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
11. Conventional chemotherapy and emerging targeted therapy for advanced adrenocortical carcinoma.
Xu YZ; Zhu Y
Anticancer Agents Med Chem; 2013 Feb; 13(2):248-53. PubMed ID: 22934700
[TBL] [Abstract][Full Text] [Related]
12. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
13. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant mitotane in adrenocortical carcinoma.
Bertherat J; Coste J; Bertagna X
N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
[No Abstract] [Full Text] [Related]
15. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for adrenocortical carcinoma.
Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant mitotane therapy of adrenal cancer - use and controversy.
Schteingart DE
N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125
[No Abstract] [Full Text] [Related]
18. Adrenocortical carcinoma.
van Ditzhuijsen CI; van de Weijer R; Haak HR
Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
[TBL] [Abstract][Full Text] [Related]
19. Current Status and Future Targeted Therapy in Adrenocortical Cancer.
Alyateem G; Nilubol N
Front Endocrinol (Lausanne); 2021; 12():613248. PubMed ID: 33732213
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant mitotane in adrenocortical carcinoma.
Lee JE
N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
[No Abstract] [Full Text] [Related]
[Next] [New Search]